Literature DB >> 18690888

High-throughput screening assays to discover small-molecule inhibitors of protein interactions.

Pierre Colas1.   

Abstract

The availability of large collections of small-molecule inhibitors of protein interactions would bear a tremendous impact both on academic and therapeutic research. The past recent years have seen a marked acceleration in the discovery of protein interaction inhibitors, through structure-based drug design but mostly through screening efforts. This article attempts to review the impressive number and variety of in vitro and cellular screening assays that have been developed and, for most of them, used successfully to identify small-molecule inhibitors of protein interactions. Various strategies aimed at improving hit rates are also reviewed, and future challenges to improve discovery success rates are discussed. The growing list of protein interaction inhibitors and the large arsenal of screening methods, now available to most laboratories or screening facilities, will probably convince an increasing number of academic and industrial scientists that protein interactions are more druggable than once feared, and that their respective research interests would greatly benefit from the discovery of protein interaction inhibitors.

Mesh:

Year:  2008        PMID: 18690888     DOI: 10.2174/157016308785739875

Source DB:  PubMed          Journal:  Curr Drug Discov Technol        ISSN: 1570-1638


  10 in total

Review 1.  A-kinase anchoring proteins as potential drug targets.

Authors:  Jessica Tröger; Marie C Moutty; Philipp Skroblin; Enno Klussmann
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

2.  Characterization and optimization of a novel protein-protein interaction biosensor high-content screening assay to identify disruptors of the interactions between p53 and hDM2.

Authors:  Drew D Dudgeon; Sunita N Shinde; Tong Ying Shun; John S Lazo; Christopher J Strock; Kenneth A Giuliano; D Lansing Taylor; Patricia A Johnston; Paul A Johnston
Journal:  Assay Drug Dev Technol       Date:  2010-08       Impact factor: 1.738

3.  Reconfiguring the AR-TIF2 Protein-Protein Interaction HCS Assay in Prostate Cancer Cells and Characterizing the Hits from a LOPAC Screen.

Authors:  Ashley T Fancher; Yun Hua; Daniel P Camarco; David A Close; Christopher J Strock; Paul A Johnston
Journal:  Assay Drug Dev Technol       Date:  2016-09-08       Impact factor: 1.738

4.  High-content positional biosensor screening assay for compounds to prevent or disrupt androgen receptor and transcriptional intermediary factor 2 protein-protein interactions.

Authors:  Yun Hua; Tong Ying Shun; Christopher J Strock; Paul A Johnston
Journal:  Assay Drug Dev Technol       Date:  2014-09       Impact factor: 1.738

5.  An in vivo multiplexed small-molecule screening platform.

Authors:  Barbara M Grüner; Christopher J Schulze; Dian Yang; Daisuke Ogasawara; Melissa M Dix; Zoë N Rogers; Chen-Hua Chuang; Christopher D McFarland; Shin-Heng Chiou; J Mark Brown; Benjamin F Cravatt; Matthew Bogyo; Monte M Winslow
Journal:  Nat Methods       Date:  2016-09-12       Impact factor: 28.547

6.  IP-FCM measures physiologic protein-protein interactions modulated by signal transduction and small-molecule drug inhibition.

Authors:  Stephen E P Smith; Anya T Bida; Tessa R Davis; Hugues Sicotte; Steven E Patterson; Diana Gil; Adam G Schrum
Journal:  PLoS One       Date:  2012-09-21       Impact factor: 3.240

7.  Potent and selective photo-inactivation of proteins with peptoid-ruthenium conjugates.

Authors:  Jiyong Lee; D Gomika Udugamasooriya; Hyun-Suk Lim; Thomas Kodadek
Journal:  Nat Chem Biol       Date:  2010-03-14       Impact factor: 15.040

Review 8.  Bone Regeneration Based on Tissue Engineering Conceptions - A 21st Century Perspective.

Authors:  Jan Henkel; Maria A Woodruff; Devakara R Epari; Roland Steck; Vaida Glatt; Ian C Dickinson; Peter F M Choong; Michael A Schuetz; Dietmar W Hutmacher
Journal:  Bone Res       Date:  2013-09-25       Impact factor: 13.567

9.  Cellular cofactors of lentiviral integrase: from target validation to drug discovery.

Authors:  Oliver Taltynov; Belete A Desimmie; Jonas Demeulemeester; Frauke Christ; Zeger Debyser
Journal:  Mol Biol Int       Date:  2012-08-07

10.  Four amino acids within a tandem QxVx repeat in a predicted extended α-helix of the Smad-binding domain of Sip1 are necessary for binding to activated Smad proteins.

Authors:  Andrea Conidi; Veronique van den Berghe; Kris Leslie; Agata Stryjewska; Hua Xue; Ye-Guang Chen; Eve Seuntjens; Danny Huylebroeck
Journal:  PLoS One       Date:  2013-10-11       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.